These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38331930)

  • 1. Prediction of ineffectiveness of biological drugs using machine learning and explainable AI methods: data from the Austrian Biological Registry BioReg.
    Ukalovic D; Leeb BF; Rintelen B; Eichbauer-Sturm G; Spellitz P; Puchner R; Herold M; Stetter M; Ferincz V; Resch-Passini J; Zwerina J; Zimmermann-Rittereiser M; Fritsch-Stork R
    Arthritis Res Ther; 2024 Feb; 26(1):44. PubMed ID: 38331930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
    BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Machine learning model for identifying important clinical features for predicting remission in patients with rheumatoid arthritis treated with biologics.
    Koo BS; Eun S; Shin K; Yoon H; Hong C; Kim DH; Hong S; Kim YG; Lee CK; Yoo B; Oh JS
    Arthritis Res Ther; 2021 Jul; 23(1):178. PubMed ID: 34229736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
    Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
    Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
    Jansen JP; Incerti D; Mutebi A; Peneva D; MacEwan JP; Stolshek B; Kaur P; Gharaibeh M; Strand V
    J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
    Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Data of Adherence and Drug Survival of Biologics in Treatment-Naïve and Treatment-experienced Adult Patients with Rheumatoid Arthritis.
    Rosenberg V; Chodick G; Xue Z; Faccin F; Amital H
    Adv Ther; 2023 Oct; 40(10):4504-4522. PubMed ID: 37566157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
    Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
    Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria.
    Rintelen B; Zwerina J; Herold M; Singer F; Hitzelhammer J; Halder W; Eichbauer-Sturm G; Puchner R; Stetter M; Leeb BF;
    BMC Musculoskelet Disord; 2016 Aug; 17(1):358. PubMed ID: 27550175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N; Lee YC; Shah N; Harrison DJ
    Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of biological disease modifying antirheumatic drugs in rheumatoid arthritis in Austria from 2008 to 2011 : A retrospective analysis of 72% of the population.
    Stamm TA; Reichardt B; Zwerina J; Ritschl V; Nell-Duxneuner V
    Wien Klin Wochenschr; 2018 Apr; 130(7-8):230-237. PubMed ID: 29445863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of biologics in patients with rheumatoid arthritis stratified by body mass index: a cohort study in a Swiss registry.
    Vallejo-Yagüe E; Burkard T; Finckh A; Burden AM;
    BMJ Open; 2024 Feb; 14(2):e074864. PubMed ID: 38331859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world retention rates of biologics in patients with rheumatoid arthritis.
    Takami K; Tsuji S
    Sci Rep; 2023 Dec; 13(1):21170. PubMed ID: 38040839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis.
    Jansen JP; Buckley F; Dejonckheere F; Ogale S
    Health Qual Life Outcomes; 2014 Jul; 12():102. PubMed ID: 24988902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mechanism of action of biological disease--modifying antirheumatic drugs].
    Takahashi N; Ishiguro N
    Nihon Rinsho; 2016 Jun; 74(6):882-6. PubMed ID: 27311173
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Nam JL; Ramiro S; Gaujoux-Viala C; Takase K; Leon-Garcia M; Emery P; Gossec L; Landewe R; Smolen JS; Buch MH
    Ann Rheum Dis; 2014 Mar; 73(3):516-28. PubMed ID: 24399231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis.
    Nakayamada S; Kubo S; Yoshikawa M; Miyazaki Y; Yunoue N; Iwata S; Miyagawa I; Hirata S; Nakano K; Saito K; Tanaka Y
    Rheumatology (Oxford); 2018 Jan; 57(1):164-174. PubMed ID: 28371836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.